Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors

References

• Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J. Clin. Invest.108(10), 1411–1415 (2001).
   PubMed Web of Science ®Google Scholar
• Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol. Rev.222, 328–340 (2008).
   PubMed Web of Science ®Google Scholar
• Kondo F, Wada K, Nagato Y et al. Biopsy diagnosis of well-differentiated hepatocellular carcinoma based on new morphologic criteria. Hepatology9(5), 751–755 (1989).
   PubMedGoogle Scholar
• Gebo KA, Chander G, Jenckes MW et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology36(5 Suppl. 1), S84–S92 (2002).
   Web of Science ®Google Scholar
• Daniele B, Bencivenga A, Megna AS, Tinessa V. α-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology127(5 Suppl. 1), S108–S112 (2004).
   PubMed Web of Science ®Google Scholar
• Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res.52(15), 4168–4174 (1992).
   PubMed Web of Science ®Google Scholar
• Labrecque S, Naor N, Thomson D, Matlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res.53(15), 3468–3471 (1993).
   PubMed Web of Science ®Google Scholar
• Lubin R, Schlichtholz B, Bengoufa D et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res.53(24), 5872–5876 (1993).
   PubMed Web of Science ®Google Scholar
• Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv. Immunol.44, 93–151 (1989).
   PubMed Web of Science ®Google Scholar
• Imai H, Nakano Y, Kiyosawa K, Tan EM. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer71(1), 26–35 (1993).
   PubMed Web of Science ®Google Scholar
• Imai H, Kiyosawa K, Chan EKL, Tan EM. Autoantibodies in viral hepatitis related hepatocellular carcinoma. Intervirology35(1–4), 73–85 (1993).
   PubMedGoogle Scholar
• Imai H, Chan EKL, Kiyosawa K, Fu X, Tan EM. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J. Clin. Invest.92(5), 2419–2426 (1993).
   PubMedGoogle Scholar
• Zhang JY, Zhu W, Imai H, Kiyosawa K, Chan EKL, Tan EM. De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin. Exp. Immunol.125(1), 3–9 (2001).
   PubMedGoogle Scholar
• Jongeneel V. Towards a cancer immunome database. Cancer Immun.1, 3 (2001).
   PubMedGoogle Scholar
• Jung DJ, Na SY, Na DS, Lee JW. Molecular cloning and characterization of CAPER, a novel co-activator of activating protein-1 and estrogen receptors. J. Biol. Chem.277(2), 1229–1234 (2002).
   PubMed Web of Science ®Google Scholar
• Dowhan DH, Hong EP, Auboeuf D et al. Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPER α and CAPER β. Mol. Cell17(3), 429–439 (2005).
   PubMed Web of Science ®Google Scholar
• Dutta J, Fan G, Gelinas C. CAPER a is a novel Rel-TAD interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-κB oncoprotein v-Rel. J. Virol.82(21), 10792–10802 (2008).
   PubMedGoogle Scholar
• Zhang JY, Chan EK, Peng XX, Tan EM. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J. Exp. Med.189(7), 1101–1110 (1999).
   PubMed Web of Science ®Google Scholar
• Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol. Cell Biol.19(2), 1262–1270 (1999).
   PubMed Web of Science ®Google Scholar
• Mueller-Pillasch F, Lacher U, Wallrap C et al. Cloning of a gene highly expressed in cancer coding for a novel KH-domain containing protein. Oncogene14(22), 2729–2733 (1997).
   PubMedGoogle Scholar
• Doyle GA, Bourdeau-Heller JM, Coulthard S, Meisner F, Ross J. Amplification in human breast cancer of a gene encoding a c-myc mRNA binding protein. Cancer Res.60(11), 2756–2759 (2000).
   PubMed Web of Science ®Google Scholar
• Zhang JY, Casiano C, Peng XX, Koziol J, Chan EKL, Tan EM. Enhancement of antibody detection in cancer using a panel of recombinant tumor-associated antigens. Cancer Epidemiol. Biomarkers Prev.12(2), 136–143 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang JY, Chan EK, Peng XX et al. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin. Immunol.100(2), 149–156 (2001).
   PubMed Web of Science ®Google Scholar
• Westley BR, May FE. Insulin-like growth factors: the unrecognized oncogenes. Br. J. Cancer72(5), 1065–1066 (1995).
   PubMedGoogle Scholar
• Cariani E, Lasserre C, Seurin D et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors and liver cirrhosis. Cancer Res.48(23), 6844–6849 (1988).
   PubMed Web of Science ®Google Scholar
• Rogler CE, Yang D, Rosetti L et al. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor II transgenic mice. J. Biol. Chem.269(19), 13779–13784 (1994).
   PubMedGoogle Scholar
• Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogenes-induced tumorigenesis, Nature369(6479), 414–417 (1994).
   PubMed Web of Science ®Google Scholar
• Soo Hoo L, Zhang JY, Chan EKL. Characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer. Oncogene21(32), 5006–5015 (2002).
   PubMed Web of Science ®Google Scholar
• Arroyo JD, Hahn H. Involvement of PP2A in viral and cellular transformation. Oncogene24(52), 7746–7755 (2005).
   PubMedGoogle Scholar
• Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr. Opin Genet. Dev.15(1), 34–41 (2005).
   PubMedGoogle Scholar
• Juntilla MR, Puustinen P, Niemela M et al. CIP2A inhibits PP2A in human malignancies. Cell130(1), 51–62 (2007).
   PubMedGoogle Scholar
• Côme C, Laine A, Chanrion M et al. CIP2A is associated with human breast cancer aggressivity. Clin. Cancer Res.15(16), 5092–5100 (2009).
   PubMed Web of Science ®Google Scholar
• Khanna A, Böckelman C, Hemmes A et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J. Natl Cancer Inst.101(11), 793–805 (2009).
   PubMedGoogle Scholar
• Landberg G, Tan EM. Characterization of a DNA-binding nuclear autoantigen mainly associated with S phase and G2 cells. Exp. Cell Res.212(2), 255–261 (1994).
   PubMed Web of Science ®Google Scholar
• Muro Y, Chan EK, Landberg G, Tan EM. A cell-cycle nuclear autoantigen containing WD40 motifs expressed mainly in S and G2 phase cells. Biochem. Biophys. Res. Comm.207(3), 1029–1037 (1995).
   PubMed Web of Science ®Google Scholar
• Moreno CS, Park S, Nelson K et al. WD40 repeat proteins striatin and S/G2 nuclear autoantigen are members of a novel family of calmodulin-binding proteins that associate with protein phosphatase 2A. J. Biol. Chem.275(8), 5257–5263 (2000).
   PubMed Web of Science ®Google Scholar
• Eichhorn PJ, Creyghton MP, Bernards, R. Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta1795(1), 1–15 (2009).
   PubMed Web of Science ®Google Scholar
• Soussi T. p53 antibodies in the sera of patients with various types of cancer. A review. Cancer Res.60(7), 1777–1788 (2000).
   PubMed Web of Science ®Google Scholar
• Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer30(4), 403–408 (1982).
   PubMed Web of Science ®Google Scholar
• Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol.15(11), 3363–3367 (1997).
   PubMed Web of Science ®Google Scholar
• Keene JD. Why is Hu where?. Shuttling of early response gene messenger RNA subsets. Proc. Natl Acad. Sci. USA96(1), 5–7 (1999).
   PubMed Web of Science ®Google Scholar
• Stockert E, Jager E, Chen YT et al. A survey of humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med.187(8), 1349–1354 (1998).
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med.3(8), 917–921 (1997).
   PubMed Web of Science ®Google Scholar
• Daniels T, Zhang J, Gutierrez I et al. Antinuclear autoantibodies in PCa: Immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate62(1), 14–26 (2005).
   PubMed Web of Science ®Google Scholar
• Lu M, Nakamura RM, Dent ED et al. Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis. Am. J. Pathol.159(3), 945–953 (2001).
   PubMed Web of Science ®Google Scholar
• Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J. Proteome Res.4(4), 1123–1133 (2005).
   PubMed Web of Science ®Google Scholar
• Old LJ, Chen YT. New paths in human cancer serology. J. Exp. Med.187(8), 1163–1167 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang JY, Megliorino R, Peng XX, Tan EM, Chen Y, Chan EKL. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J. Hepatol.46(1), 107–114 (2007).
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhou Y, Qiu S et al. Autoantibodies to tumor-associated antigens combined with abnormal α-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Lett.289(1), 32–39 (2010).
   PubMedGoogle Scholar
• Yamamoto A, Shimizu E, Takeuchi E et al. Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients. Oncology56(2), 129–133 (1999).
   PubMed Web of Science ®Google Scholar
• Covini G, Chan EK, Nishioka M, Morshed SA, Reed SI, Tan EM. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology25(1), 75–80 (1997).
   PubMed Web of Science ®Google Scholar
• Kao H, Marto JA, Hoffmann TK et al. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J. Exp. Med.194(9), 1313–1323 (2001).
   PubMed Web of Science ®Google Scholar
• Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl Acad. Sci. USA93(24), 13742–13747 (1996).
   PubMed Web of Science ®Google Scholar
• Looi K, Megliorino R, Shi FD, Peng VV, Chen Y, Zhang JY. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncology Rep.16(5), 1105–1110 (2006).
   PubMed Web of Science ®Google Scholar
• Yoon HJ, Donahue TF. The sui1 suppressor locus in Saccharomyces cerevisiae encodes a translation factor that functions during tRNAiMet recognition of the start codon. Mol. Cell. Biol.12(1), 248–260 (1992).
   PubMed Web of Science ®Google Scholar
• Lian Z, Pan J, Liu J et al. The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis. Oncogene18(9), 1677–1687 (1999).
   PubMed Web of Science ®Google Scholar
• Gildea JJ, Harding MA, Seraj MJ, Gulding KM, Theodorescu D. The role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer Res.62(4), 982–985 (2002).
   PubMed Web of Science ®Google Scholar
• Lim KH, Baines AT, Fiordalisi JJ et al. Activation of RalA is critical for Ras- induced tumorigenesis of human cells. Cancer Cell7(6), 533–545 (2005).
   PubMed Web of Science ®Google Scholar
• Wang X, Yu J, Sreekumar A et al. Autoantibody signatures in prostate cancer. N. Engl. J. Med.353(12), 1224–1235 (2005).
   PubMed Web of Science ®Google Scholar